BML Investment Partners, L.P. 13D and 13G filings for AcelRx Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-01-27 2:51 pm Sale |
2022-01-27 | 13G | AcelRx Pharmaceuticals, Inc. ACRX |
BML Investment Partners, L.P. | 0 0.000% |
-297,800 (Position Closed) |
Filing |
| 2021-02-10 2:58 pm Purchase |
2021-02-10 | 13G | AcelRx Pharmaceuticals, Inc. ACRX |
BML Investment Partners, L.P. | 297,800 6.000% |
59,910 (+25.18%) |
Filing |
| 2020-10-27 4:04 pm Unchanged |
2020-10-09 | 13G | AcelRx Pharmaceuticals, Inc. ACRX |
BML Investment Partners, L.P. | 237,890 5.300% |
0 (Unchanged) |
Filing |
| 2020-10-27 3:50 pm Purchase |
2020-10-09 | 13G | AcelRx Pharmaceuticals, Inc. ACRX |
BML Investment Partners, L.P. | 237,890 5.300% |
237,890 (New Position) |
Filing |